Financial Data and Key Metrics Changes - The company reported a 7% increase in net revenue for Q4 2024, totaling $33.8 million, compared to the prior year [18] - Gross margins increased by 2% year-over-year to 52.2% [8] - Operating income rose by 69% to $6.9 million, while adjusted EBITDA increased by 13% to $25.3 million, with an adjusted EBITDA margin of 18.8% for the full year [9][10] Business Line Data and Key Metrics Changes - Revenue growth was observed across almost all business lines, with oncology and pain management increasing by 6.1% and 14.7% respectively [11] - Equipment rentals in device solutions grew by 13.6%, and equipment sales increased by 20.6% due to a significant transaction in Q3 [11] - Advanced wound care revenue surged by 342%, while the wound care segment overall was below expectations due to a strategic pause in onboarding new initiatives [12][19] Market Data and Key Metrics Changes - The company noted a strong demand for advanced wound care products and biomed services, indicating a ripe opportunity for growth in these areas [41] - The addressable market for Chemo Mouthpiece is estimated to be around $500 to $600 million, highlighting significant potential for revenue generation [67] Company Strategy and Development Direction - The company aims for revenue growth of 8% to 10% in 2025, with adjusted EBITDA margins expected to exceed 18.8% [34] - Focus on less capital-intensive revenue sources, such as biomedical services and advanced wound care supplies, is expected to drive future growth [26][34] - The company is strategically pausing some wound care initiatives to ensure quality and alignment with existing resources before ramping up in 2025 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving growth across all business lines in 2025, particularly in advanced wound care and biomed [43] - The sales cycle for Chemo Mouthpiece is anticipated to gain momentum in the coming months, with clinical studies expected to enhance market adoption [49][70] - The company expects to see benefits from improvements in the referral process throughout 2025, with gradual enhancements in operational efficiency [55] Other Important Information - The effective tax rate for Q4 2024 was reported at 59%, primarily due to equity compensation deductions and other non-cash tax expenses [22][23] - The company’s net debt decreased to $23.3 million, with strong liquidity reserves of over $51 million as of December 31, 2024 [27][28] Q&A Session Summary Question: Growth expectations for Advanced Wound Care products - Management indicated that Advanced Wound Care is expected to drive most of the growth in 2025, with significant opportunities from DME partners [41][43] Question: Feedback on Chemo Mouthpiece from oncology centers - Management noted growing interest and small orders for Chemo Mouthpiece, with expectations for broader adoption following the publication of clinical studies [46][49] Question: Improvements in the referral process - Management explained that improvements in the referral process will ramp throughout the year, with some benefits expected in Q1 [53][55] Question: Addressable market for Chemo Mouthpiece and Dignitana - Management stated that Chemo Mouthpiece has a large addressable market, while Dignitana represents a smaller but significant opportunity [66][67] Question: Factors contributing to EBITDA margin improvement - Management highlighted continued efficiencies in biomed and growth in other areas as key contributors to improved EBITDA margins [72][75]

Core Viewpoint - American Public Education, Inc. (APEI) is expected to report its fourth-quarter 2024 results on March 6, with a focus on revenue growth and enrollment trends across its segments [1]. Financial Performance - In the last reported quarter, APEI's earnings per share (EPS) exceeded the Zacks Consensus Estimate by 300%, while revenues fell short by 0.3%. Year-over-year, revenues increased by 1.5% and EPS rose by 100% [2]. - The Zacks Consensus Estimate for the fourth-quarter EPS is stable at 54 cents, indicating a 15.6% decrease from the previous year's EPS of 64 cents. Revenue estimates are pegged at $161.6 million, suggesting a 5.7% year-over-year rise [3]. Enrollment and Revenue Growth - APEI's fourth-quarter revenues are anticipated to increase due to strong performance across all segments, particularly in the American Public University System (APUS) and Hondros College of Nursing (HCN) [4]. - APUS is expected to see total net course registrations grow by 4% to 6%, driven by military-affiliated programs. HCN's enrollment is projected to rise by 19% to 3,700 students, while Rasmussen University (RU) is expected to have a 4% increase in student enrollment to 14,600 [6]. Segment Revenue Expectations - For the fourth quarter, revenues in the APUS and HCN segments are expected to increase by 2.8% to $81.6 million and by 20.6% to $19 million, respectively. RU segment revenues are predicted to grow by 5.4% to $55.4 million [7]. Margin and Income Projections - APEI is expected to report net income between $9 million and $11 million, down from $11.5 million a year ago, translating to EPS between 47 cents and 56 cents [9]. - Adjusted EBITDA is projected to be between $23 million and $26 million, compared to $25.7 million a year ago, with adjusted EBITDA margins expected to decline by 70 basis points to 16.1% [9]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for APEI, as the Earnings ESP stands at 0.00% and the company holds a Zacks Rank of 3 (Hold) [10][11].

Financial Highlights - Full year revenue reached a record of $123 billion[3] - Non-Pipeline revenues also reached a record level[3] - Total Backlog increased to $143 billion, a sequential increase of $440 million and a year-over-year growth of $19 billion[3] - Record FY Adjusted EBITDA increased 19% year-over-year, with margins improving 110 bps[3] - FY Adjusted EPS increased $214, or 118%, year-over-year[3] - Record Cash Flow from Operations reached $11 billion[3] Segment Results (2024) - Communications revenue was $346 billion[7] - Clean Energy and Infrastructure revenue was $2682 billion[7] - Power Delivery revenue was $4092 billion[7] - Pipeline Infrastructure revenue was $2134 billion[7] Q4 2024 Backlog - Total backlog reached $143 billion, up 15%, or $19 billion year-over-year, and $440 million, or 3% sequentially[11] - Clean Energy and Infrastructure backlog grew by ~$11 billion year-over-year to ~$42 billion[11] 2025 Guidance - Revenue is projected to be $1345 billion[19] - Adjusted EBITDA is expected to be between $11 billion and $115 billion[19] - Adjusted Diluted EPS is projected to be between $535 and $584[19] - Cash flow from operations is anticipated to approximate $700 million[24]

Financial Performance & Portfolio Composition - The company's pro-rata annualized cash NOI totaled $413.912 million, with ISHC contributing 58.8%, OM 19.7%, SHOP 12.2%, Triple-Net Leased Properties 7.3%, and Debt Security Investment 2.0%[10] - Same-store ISHC revenues increased by 9.1% from Q4 2023 to $284.646 million in Q4 2024, and 7.8% from FY 2023 to $1.094 billion in FY 2024[15] - Same-store SHOP revenues increased by 11.5% from Q4 2023 to $44.793 million in Q4 2024, and 11.8% from FY 2023 to $174.310 million in FY 2024[26] - Same-store Triple-Net Leased Properties revenues increased by 1.0% from Q4 2023 to $7.597 million in Q4 2024, and 2.8% from FY 2023 to $30.583 million in FY 2024[31] Outpatient Medical (OM) - OM properties' ending occupancy was 87.9% as of December 31, 2024[20] - Same-store OM revenues increased by 2.1% from Q4 2023 to $31.960 million in Q4 2024, and 0.7% from FY 2023 to $127.722 million in FY 2024[20] Debt and Lease Expirations - Debt maturities and principal payments total $1.685 billion, with a weighted average interest rate of 4.42%[39] - In 2025, $14.576 million (13.4%) of OM ABR and $4.011 million (100%) of interest income are expiring[36] 2025 Guidance - The company anticipates total portfolio same-store NOI growth of 7.0% - 10.0% in FY 2025[45]

Financial Performance - Q4 2024 revenue reached $1,118 million, a 4.8% increase, but excluding political revenue, it decreased by 1.8%[10] - Consolidated Adjusted EBITDA for Q4 2024 was $246 million, up 18.2% from $208 million in Q4 2023[10] - Full year 2025 consolidated revenue is expected to be approximately flat, while Adjusted EBITDA is projected to be around $770 million[10] - Free cash flow was negative $(24) million, but excluding Debt Exchange Transaction impacts, it was $111 million[10] - Full year 2024 revenue was $3,854.5 million, a 2.8% increase from $3,751.0 million in 2023[48] - Full year 2024 Adjusted EBITDA was $705.6 million, a 1.3% increase from $696.6 million in 2023[48] Segment Performance - Digital Audio Group revenue increased by 7% to $339 million, with podcast revenue up 6% to $140 million and digital revenue excluding podcast up 7% to $199 million[10] - Multiplatform Group revenue remained flat at $684 million, but excluding political revenue, it decreased by 5%[10] - Audio & Media Services Group revenue increased significantly by 44.7% to $97.8 million[12] Debt and Liquidity - The company completed a debt exchange transaction, exchanging approximately $4.8 billion of existing debt and extending maturities by three years[10] - The debt exchange resulted in the lowest net debt in the company's history[10] - Cash balance and total available liquidity were $260 million and $686 million, respectively, as of December 31, 2024[10]

Financial Performance & Guidance - Kinetik achieved record financial results in 2024, with Adjusted EBITDA of $971.1 million, representing a 16% year-over-year growth[7, 12] - The company anticipates 2025 Adjusted EBITDA to be in the range of $1.09 billion to $1.15 billion, with a midpoint of $1.12 billion, reflecting a 15% year-over-year increase[19, 31] - Kinetik expects its 4Q25E annualized Adjusted EBITDA to exceed $1.2 billion[19] - Capital expenditures for 2024 were $264.5 million, resulting in a reinvestment ratio of 27%[11, 12] - The company projects 2025 capital expenditures to be between $450 million and $540 million, with a midpoint of $495 million[19, 31] Segment Performance - Midstream Logistics contributed $614.1 million, or 62%, to the total Adjusted EBITDA in 2024[12] - Pipeline Transportation accounted for $377.6 million, or 38%, of the total Adjusted EBITDA in 2024[12] - In 4Q24, Midstream Logistics Adjusted EBITDA was $150 million, a 3% increase year-over-year, while Pipeline Transportation Adjusted EBITDA was $92 million, a 9% increase year-over-year[17, 18] Growth & Strategy - Kinetik is strategically investing in projects like the Kings Landing Complex (adding 220 Mmcfpd of processing capacity), the Eddy County Project, and the ECCC Pipeline to drive future growth[19, 30] - The company expects approximately 20% year-over-year growth in gas processed volumes across its system in 2025[31, 40] - Kinetik aims for a leverage target of 3.5x and is currently at 3.4x, with a goal of achieving investment-grade credit ratings[5, 54]

Company Overview - Eventbrite aims to be the indispensable marketplace for live experiences[7] - The company is a scaled and trusted events marketplace with a large consumer audience, averaging 89 million monthly users and 270 million free and paid tickets in 2024[13] - Over 47 million events were held on the platform in 2024[17] Financial Performance & Metrics - Q4 2024 paid ticket volume was 216 million, a 10% year-over-year decrease, but improved 4 percentage points from Q3[64] - Q4 2024 net revenue was $765 million, a 13% year-over-year decline[64] - Q4 2024 net loss was $84 million, with an adjusted EBITDA of $65 million[64] - For FY 2024, Eventbrite's gross booking value was $33 billion[26] - FY 2024 net revenue was $3251 million[67] Growth Strategy - The company focuses on strategic inventory, elevating visibility and discoverability, developing self-sign-on features, and monetizing its network to drive growth[42] - Eventbrite is focused on returning to revenue growth, driven by simplified pricing and packaging, and Eventbrite Ads adoption[54] - 49% of total tickets sold were influenced by Eventbrite-driven demand in Q4 2024[39] 2025 Outlook - The company anticipates Q1 2025 net revenue to be in the range of $71 million to $74 million[70] - Full year 2025 net revenue is expected to be in the range of $295 million to $310 million, impacted by the elimination of organizer fees, resulting in an approximately $20 million revenue headwind compared to 2024[71, 72]

Financial Performance in 4Q24 - Revenue reached $1.1 billion, a 25% increase compared to $870 million in 4Q23[6, 27] - Gross profit was $85 million, up from $72 million in 4Q23, with a gross margin of 7.8%[6] - Contribution Profit increased to $38 million from $30 million in 4Q23, resulting in a Contribution Margin of 3.5%[6] - Adjusted EBITDA loss improved to $(49) million from $(69) million in 4Q23[7] - The company purchased 2,951 homes in 4Q24, compared to 3,683 homes in 4Q23[28] Full Year 2024 Results - Full-year revenue was $5.2 billion, down from $6.9 billion in 2023[27] - Full-year gross margin increased to 8.4% from 7.0% in 2023[5] - Contribution Margin was 4.7%, a significant improvement from (3.7)% in 2023[5] - The company acquired 14,684 homes, a 31% increase compared to 2023[5, 28] - Adjusted EBITDA loss for the full year was $(142) million, an improvement from $(627) million in 2023[33] Outlook for 1Q25 - Revenue is projected to be between $1.0 billion and $1.075 billion[39] - Contribution Profit is expected to range from $40 million to $50 million, with a Contribution Margin of 4.0% to 4.7%[39] - Adjusted EBITDA loss is anticipated to be between $(50) million and $(40) million[39]

Fourth Quarter & Full-Year 2024 Earnings Conference Call February 27, 2025 LGTMs: Date: Andrew T. LGTM via email 2/26/25 Peter K. LGTM 2/26/25 Legal (Karen / Peter R.) 2/26/25 Accounting (#s review) 2/25/2025 Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including, without limitation, statements regarding future events and Clover Health Investments, Corp.'s ("Clover Health," "we," "our," or "us") expectations regarding Adjusted EBITDA, Adjusted Net i ...

Company Overview - IBP has a national platform of over 250 locations serving all 48 continental states and the District of Columbia[16] - In 2024, Insulation accounted for 60% of revenue, while New Single Family represented 57% of the end-market revenue[18] - The company has generated over $1 billion in free cash flow in five years[25] - From 2020 to 2024, IBP allocated $579 million (50%) to acquisitions, $246 million (21%) to share repurchases, and $323 million (28%) to dividends[33] - An established IBP branch generates ~$4,400 per residential permit, while a developing branch generates ~$2,200 per residential permit[43] Financial Performance - IBP's residential sales per completion more than doubled from $555 in 2015 to $1,308 in 2024[55] - Net revenue increased from $16532 million in 2020 to $29413 million in 2024, a 59% growth[57] - Adjusted EBITDA increased from $2456 million in 2020 to $5114 million in 2024[57] - Net Debt / Adjusted EBITDA was 108x as of December 31, 2024[69] - Adjusted Gross Profit margin was 338% in 2024[57]